KBC, the Belgian financial group, is advising a GlaxoSmithKline spin-off on a possible flotation on the Alternative Investment Market this autumn.

Allergy Therapeutics, the biotech company that was spun off from GlaxoSmithKline in 1998, said it was considering several options to raise money for expansion, including a flotation on the junior market.